-- Announcement on Obtaining Registration Approval of Application for Issuance of Shares to Specific Objects by China Securities Regulatory Commission
Securities code: 600789 Securities abbreviation: Lukang Pharmaceutical Announcement number: 2025-050
Shandong Lukang Pharmaceutical Co., Ltd.
Announcement on Obtaining Registration Approval from the China Securities Regulatory Commission for Application to Issuance of Stocks to Specific Objects
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Shandong Lukang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Approval for the Registration of Shandong Lukang Pharmaceutical Co., Ltd.'s Issuance of Stocks to Specific Targets" (CSRC Permit [2025] No. 2158) issued by the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"). The main contents are as follows:
1. Agree with your company’s registration application to issue stocks to specific objects.
- Your company’s issuance should be implemented in strict accordance with the application documents and issuance plan submitted to the Shanghai Stock Exchange.
3. This approval shall be valid for 12 months from the date of registration approval.
- From the date of consent to registration to the end of this issuance, if any major event occurs in your company, it should be reported to the Shanghai Stock Exchange in a timely manner and handled in accordance with relevant regulations.
The company's board of directors will handle matters related to the issuance of stocks to specific objects within the prescribed period in accordance with the above-mentioned approval documents and relevant laws and regulations, as well as the authorization of the company's shareholders' meeting, and will perform information disclosure obligations in a timely manner. Investors are kindly requested to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Shandong Lukang Pharmaceutical Co., Ltd.
September 30, 2025